Why It Matters
These developments illustrate how AI is becoming a practical utility for everyday scientists, potentially accelerating therapeutic discovery. The FDA’s pivot on an mRNA flu vaccine signals shifting regulatory attitudes that could unlock a new class of vaccines, while Gilead’s CAR‑T acquisition underscores the high‑stakes race to dominate next‑generation cancer therapies. Together, they highlight the intersecting forces of technology, policy, and capital shaping the future of biotech.
Key Takeaways
- •Tamarin Bio raises $13.6M for AI model coordination platform.
- •Platform offers 200+ models, simplifying AI for wet‑lab researchers.
- •FDA reverses refusal, will review Moderna mRNA‑1010 flu vaccine.
- •Moderna shares rise 6% after FDA about‑face, still below peak.
- •Gilead acquires Arcelex for $7.8B, targeting BCMA CAR‑T therapy.
Pulse Analysis
The AI infrastructure moment is gaining traction as Tamarin Bio secures a $13.6 million Series A to launch a model‑coordination platform. By aggregating over 200 pre‑trained tools—including AlphaFold and ARF Diffusion—into a single, user‑friendly interface, the company removes coding barriers for wet‑lab biologists. This democratization accelerates hypothesis testing and streamlines drug‑discovery workflows, positioning Tamarin as a pivotal bridge between computational breakthroughs and experimental biology.
In parallel, the FDA’s abrupt reversal on Moderna’s mRNA‑1010 seasonal flu vaccine underscores the volatile regulatory landscape for novel RNA therapeutics. After a Type A meeting, the agency agreed to review the application, targeting an August 5 decision under PDUFA. Moderna’s revised strategy—seeking full approval for ages 50‑64 and accelerated approval for seniors—has already nudged the stock up 6%, though it remains far below its 2021 peak. The outcome will signal whether mRNA platforms can expand beyond COVID‑19 into broader vaccine portfolios.
The cancer‑therapy arena also saw heavyweight moves. Gilead’s $7.8 billion acquisition of Arcelex secures the BCMA‑directed CAR‑T candidate AnidoCell, positioning the company against J&J’s Carvykti in the multiple‑myeloma market. Meanwhile, Estellus’s partnership with VIR biotech to co‑develop the ProX10‑masked T‑cell engager VIR‑5500 highlights a plug‑and‑play approach to prostate‑cancer immunotherapy, offering a strategic hedge as Xtandi’s patent expires. Together, these deals illustrate how AI‑enabled platforms and strategic M&A are reshaping biotech pipelines and investor sentiment in 2026.
Episode Description
In the industry news section of this week’s episode, we kick things off with Tamarind Bio’s efforts to develop user-friendly artificial intelligence tools for science researchers. Then we examine the impact of the U.S. Food and Drug Administration’s reversal on its earlier refusal to review Moderna’s mRNA vaccine for the flu, discuss Gilead’s acquisition of Arcellx to expand its cancer therapy pipeline, and dive into Takeda’s investment in Vir Biotech’s prostate cancer candidate. Then on the research front, we get into the science behind new protein-like polymers engineered to target and degrade some of cancer’s most challenging driver proteins. And we discuss a potential control switch for CAR T cells that could make these immunotherapies much safer.
Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, Uduak Thomas and Alex Philippidis for a discussion of the latest biotech and biopharma news.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
Tamarind Bio Secures $13.6M Series A to Make AI More Accessible for Biology
By Fay Lin, PhD, GEN Edge, February 24, 2026
StockWatch: FDA Reversal Boosts Moderna, But Not Other Vaccine Companies
By Alex Philippidis, GEN Edge, February 21, 2026
Gilead to Acquire Arcellx for $7.8B, Adding Anito-Cel to Cancer Pipeline
By Alex Philippidis, GEN Edge, February 23, 2026
Astellas, Vir Biotechnology Launch Up-to-$1.7B Prostate Cancer Collaboration
By Alex Philippidis, GEN, February 26, 2026
New Protein-Like Polymers Target, Degrade “Undruggable” Proteins Driving Cancer
GEN, February 11, 2026
Drug-Controlled CAR T Cells May Enable Safer Immunotherapy
GEN, February 23, 2026
Touching Base Podcast
Hosted by Corinna Singleman, PhD
Behind the Breakthroughs
Hosted by Jonathan D. Grinstein, PhD
Hosted on Acast. See acast.com/privacy for more information.
Show Notes
0
Comments
Want to join the conversation?
Loading comments...